BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30006062)

  • 41. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 9-Bromo-2,3-diethylbenzo[de]chromene-7,8-dione (MSN54): A novel non-intercalative topoisomerase II catalytic inhibitor.
    Mai YW; Liang CC; Ou JB; Xie HT; Chen SB; Zhou DC; Yao PF; Huang ZS; Wang H; Huang SL
    Bioorg Chem; 2021 Sep; 114():105097. PubMed ID: 34171594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
    Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
    Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
    Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
    PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.
    Yadav AA; Wu X; Patel D; Yalowich JC; Hasinoff BB
    Bioorg Med Chem; 2014 Nov; 22(21):5935-49. PubMed ID: 25282653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.
    Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A
    Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
    Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
    J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
    Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
    Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
    Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
    Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, DNA and protein interactions and human topoisomerase inhibition of novel Spiroacridine derivatives.
    Gouveia RG; Ribeiro AG; Segundo MÂSP; de Oliveira JF; de Lima MDCA; de Lima Souza TRC; de Almeida SMV; de Moura RO
    Bioorg Med Chem; 2018 Dec; 26(22):5911-5921. PubMed ID: 30420325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
    Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
    Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.
    Meyer KN; Kjeldsen E; Straub T; Knudsen BR; Hickson ID; Kikuchi A; Kreipe H; Boege F
    J Cell Biol; 1997 Feb; 136(4):775-88. PubMed ID: 9049244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
    Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
    Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
    Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
    Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A two-drug model for etoposide action against human topoisomerase IIalpha.
    Bromberg KD; Burgin AB; Osheroff N
    J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines.
    Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES
    Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.